The lung cancer paradox: time for action

Thorax. 2002 Oct;57 Suppl 2(Suppl 2):II57-II63.

Authors

R C Rintoul¹, T Sethi

Affiliation

¹ Lung Inflammation Group, Centre for Inflammation Research, Medical School, University of Edinburgh, UK.

PMID: 12364713
PMCID: PMC1766005

No abstract available

Publication types

Review

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / surgery*
Carcinoma, Non-Small-Cell Lung / therapy
Cisplatin / therapeutic use
Female
Humans
Lung Neoplasms / mortality
Lung Neoplasms / surgery*
Lung Neoplasms / therapy
Male
Medical Oncology
Middle Aged
Patient Selection*
Prejudice
Pulmonary Medicine
Referral and Consultation
Scotland / epidemiology
Survival Rate
Treatment Failure

Substances

Cisplatin